With the growing number of clinical evidence on the superiority of EGFR-TKI and MET-TKI combination therapy over chemotherapy, we anticipate the consensus on the use of the combination therapy as the standard of care for the management of NSCLC after MET amplification-mediated resistance to EGFR-TKI. This evidence concerns the gene MET and non-small cell lung carcinoma.